MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12014-025-09527-7

Медицинская библиотека · Clinical proteomics · 2025

ARTN and CCL23 predicted chemosensitivity in acute myeloid leukemia: an Olink® proteomics approach.

Wu Ting-Shuan, Hsiao Tzu-Hung, Chen Chung-Hsing, Li Hsin-Ni, Hung Miao-Neng, Jhan Pei-Pei, Tsai Jia-Rung, Teng Chieh-Lin Jerry

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

The standard "7 + 3" induction results in 30% of de novo acute myeloid leukemia (AML) patients not achieving complete remission (CR). We aimed to utilize the Olink® platform to compare the bone marrow plasma proteomic profiles of newly diagnosed de novo AML patients who did and did not achieve CR following "7 + 3" induction treatment.

METHODS

This prospective study included 43 untreated AML patients, stratified into CR (n = 29) and non-CR (n = 14) groups based on their response to "7 + 3" induction therapy. We employed the Olink® Explore-384 Inflammation platform for proteomic analysis to investigate differences in bone marrow plasma protein levels between the CR and non-CR groups.

RESULTS

Proteomic analysis demonstrated that the CR group exhibited significantly higher bone marrow plasma levels of ARTN and CCL23 than did the non-CR group. Immunohistochemical staining confirmed a higher proportion of tissue samples with intense staining for ARTN (25.40% vs. 7.05%, p = 0.013) and CCL23 (24.14% vs. 14.29%, p = 0.039) in the CR group. These findings were corroborated by bulk-RNA-seq, which indicated significantly elevated mRNA expression levels of ARTN (1.93 vs. -0.09; p = 0.003) and CCL23 (1.50 vs. 0.12; p = 0.021) in the CR group. The Human Protein Atlas provided external support for our findings.

CONCLUSIONS

The results suggest that ARTN and CCL23 may serve as biomarkers for predicting responsiveness to the "7 + 3" induction in untreated AML. Using an enzyme-linked immunosorbent assay to identify the roles of ARTN and CCL23 in predicting AML chemosensitivity may enhance clinical applicability in the future.

Для цитирования: Wu Ting-Shuan, Hsiao Tzu-Hung, Chen Chung-Hsing, Li Hsin-Ni, Hung Miao-Neng, Jhan Pei-Pei, Tsai Jia-Rung, Teng Chieh-Lin Jerry. ARTN and CCL23 predicted chemosensitivity in acute myeloid leukemia: an Olink® proteomics approach.. Clinical proteomics. 2025. DOI: 10.1186/s12014-025-09527-7.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.